Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 8 of 382 rows for Microglia / neuroinflammation target (preclinical). One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Microglia / neuroinflammation target (preclinical) Medicines | Treatment |
Benefit
whyDirection is for peripheral cancer in AD mice: tumour-secreted cystatin-C bound amyloid oligomers and activated microglial TREM2, enabling degradation of existing plaques and rescuing cognition; the effect was abolished by microglial deletion or mutation of TREM2 or cystatin-C. Mouse work with no human outcome. |
Amyloid plaque load and cognition in AD mice bearing peripheral tumours, and dependence on microglial TREM2 and cystatin-C | None | not stated | not established — pubmed abstract reports no numeric effect size. |
Cell
2026 ✓ Peer-reviewed PMID 41576952 |
| Microglia / neuroinflammation target (preclinical) Medicines | Treatment |
Benefit
whyDirection is for lowering PU.1 in microglia, which reduced the severity of amyloid pathology in mice; microglia-specific CD28 deficiency did the opposite and increased plaque load. Mouse work with no human outcome. |
Severity of amyloid pathology in mouse models | None | not stated | not established — pubmed abstract reports no numeric effect size. |
Nature
2025 ✓ Peer-reviewed PMID 41193812 |
| Microglia / neuroinflammation target (preclinical) Medicines | Treatment |
No direction reported
whyA descriptive transcriptional atlas: it maps expression changes, isoform usage, co-expression modules and disease subtypes in microglia from post-mortem brains and estimates no effect of an exposure. |
Microglial gene-expression changes associated with dementia severity and neuropathological lesions (ex vivo human microglia) | None | 189 | not established — pubmed abstract reports no numeric effect size. |
Nature Neuroscience
2025 ✓ Peer-reviewed PMID 40760184 |
| Microglia / neuroinflammation target (preclinical) Medicines | Treatment |
Benefit
whyDirection is for deleting TIM-3 in microglia: it increased phagocytic activity, shifted microglia to the disease-associated state, reduced amyloid pathology and improved cognitive impairment in 5xFAD mice. Mouse work with no human outcome. |
Microglial phagocytosis, amyloid pathology and cognition in 5xFAD mice after microglia-targeted deletion of TIM-3 (Havcr2) | None | not stated | not established — pubmed abstract reports no numeric effect size. |
Nature
2025 ✓ Peer-reviewed PMID 40205047 |
| Microglia / neuroinflammation target (preclinical) Medicines | Treatment |
Benefit
whyDirection is for blocking the ZBP1-RIPK1 axis: genetic deletion of Zbp1 or inhibition of RIPK1 attenuated neuroinflammation, amyloid pathology and behavioural deficits in AD mice, after showing that amyloid-induced oxidised mitochondrial DNA forms Z-DNA sensed by ZBP1 in microglia. Mouse work with no human outcome. |
Neuroinflammation, amyloid pathology and behavioural deficits in an AD mouse model after Zbp1 deletion or RIPK1 inhibition | None | not stated | not established — pubmed abstract reports no numeric effect size. |
Immunity
2025 ✓ Peer-reviewed PMID 40902587 |
| Microglia / neuroinflammation target (preclinical) Medicines | Treatment |
Benefit
whyDirection is for removing the granzyme K-producing CD103-negative CD8+ T cells: their ablation ameliorated cognitive decline and reduced neuropathology in 3xTg-AD mice, and granzyme K caused neuronal dysfunction and tau hyperphosphorylation via PAR-1. Mouse and cell work with no human outcome. |
Cognitive decline and neuropathology in 3xTg-AD mice after ablation of brain CD103-negative CD8+ T cells, and granzyme K-PAR-1 neurotoxicity in cells | None | not stated | not established — pubmed abstract reports no numeric effect size. |
Nature Communications
2025 ✓ Peer-reviewed PMID 40993111 |
| Microglia / neuroinflammation target (preclinical) Medicines | Treatment |
Benefit
whyDirection is for inhibiting C1q, C3 or the microglial receptor CR3, which reduced phagocytic microglia and early synapse loss; C1q was necessary for soluble amyloid-beta oligomers to damage synapses. Mouse work with no human outcome. |
Early synapse loss in Alzheimer mouse models | None | not stated | not established — pubmed abstract reports no numeric effect size. |
Science
2016 ✓ Peer-reviewed PMID 27033548 |
| Microglia / neuroinflammation target (preclinical) Medicines | Treatment |
Benefit
whyDirection is for NLRP3 or caspase-1 deficiency, which largely protected the mice from spatial memory loss and reduced amyloid deposition; the human data are limited to raised active caspase-1 in post-mortem MCI and Alzheimer brains. |
Spatial memory loss and amyloid deposition in APP/PS1 mice | None | not stated | not established — pubmed abstract reports no numeric effect size. |
Nature
2013 ✓ Peer-reviewed PMID 23254930 |
Last updated